IL286900B2 - Intracellular chloride concentration modulators - Google Patents

Intracellular chloride concentration modulators

Info

Publication number
IL286900B2
IL286900B2 IL286900A IL28690021A IL286900B2 IL 286900 B2 IL286900 B2 IL 286900B2 IL 286900 A IL286900 A IL 286900A IL 28690021 A IL28690021 A IL 28690021A IL 286900 B2 IL286900 B2 IL 286900B2
Authority
IL
Israel
Prior art keywords
benzoic acid
dimethylsulfamoyl
trifluorooctylamino
compound
mmol
Prior art date
Application number
IL286900A
Other languages
English (en)
Hebrew (he)
Other versions
IL286900A (en
IL286900B1 (en
Original Assignee
Fondazione St Italiano Tecnologia
Fond Telethon Ets
Udidi Genovaunversita Degli St
Univ Bologna Alma Mater Studiorum
Univ Degli Studi Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione St Italiano Tecnologia, Fond Telethon Ets, Udidi Genovaunversita Degli St, Univ Bologna Alma Mater Studiorum, Univ Degli Studi Genova filed Critical Fondazione St Italiano Tecnologia
Publication of IL286900A publication Critical patent/IL286900A/en
Publication of IL286900B1 publication Critical patent/IL286900B1/en
Publication of IL286900B2 publication Critical patent/IL286900B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL286900A 2019-04-02 2020-04-02 Intracellular chloride concentration modulators IL286900B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201900004929 2019-04-02
PCT/IB2020/053158 WO2020202072A1 (en) 2019-04-02 2020-04-02 Modulators of intracellular chloride concentration

Publications (3)

Publication Number Publication Date
IL286900A IL286900A (en) 2021-10-31
IL286900B1 IL286900B1 (en) 2024-11-01
IL286900B2 true IL286900B2 (en) 2025-03-01

Family

ID=67185615

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286900A IL286900B2 (en) 2019-04-02 2020-04-02 Intracellular chloride concentration modulators

Country Status (10)

Country Link
US (1) US20220184008A1 (enExample)
EP (1) EP3947345A1 (enExample)
JP (1) JP7676317B2 (enExample)
KR (1) KR20220022051A (enExample)
CN (2) CN120661491A (enExample)
AU (1) AU2020251023B2 (enExample)
CA (1) CA3135339A1 (enExample)
IL (1) IL286900B2 (enExample)
SG (1) SG11202110950XA (enExample)
WO (1) WO2020202072A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300007521A1 (it) 2023-04-18 2024-10-18 Iama Therapeutics S R L Processo per la preparazione di derivati dell'acido sulfamoilbenzoico
WO2025257786A1 (en) * 2024-06-13 2025-12-18 Iama Therapeutics S.R.L. Benzoimidazole derivatives as nkcc1 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1471237A (en) * 1974-03-18 1977-04-21 Hoechst Ag Basically substituted benzenesulphonamides and process for preparing them
EP0056970A1 (de) * 1981-01-22 1982-08-04 Hoechst Aktiengesellschaft Basisch substituierte Anthranilsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2000042004A1 (fr) * 1999-01-15 2000-07-20 Universite De Liege Derives de sulfonamides benzeniques et leurs utilisations
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
WO2007058960A1 (en) * 2005-11-10 2007-05-24 Adolor Corporation Sulfamoyl benzamides as cannabinoid receptor modulators
WO2008052190A2 (en) * 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2010085352A2 (en) * 2009-01-22 2010-07-29 Neurotherapeutics Pharma, Inc. Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493584A (en) * 1966-02-21 1970-02-03 Smithkline Corp 4-substituted amino-5-sulfamoylbenzoic acid derivatives and preparation
DE2442851A1 (de) * 1974-09-06 1976-03-18 Hoechst Ag Basisch substituierte 3-sulfamoylbenzoesaeurederivate und verfahren zu ihrer herstellung
DE2517183A1 (de) * 1975-04-18 1976-10-28 Hoechst Ag Basisch substituierte 5-sulfamoyl- anthranilsaeurederivate und verfahren zu ihrer herstellung
US6355633B1 (en) * 1999-03-31 2002-03-12 American Home Products Corporation Aryl sulfonic acids and derivatives as FSH antagonists
WO2000058277A1 (en) * 1999-03-31 2000-10-05 American Home Products Corporation Aryl sulfonic acids and derivatives as fsh antagonists
JP2002201172A (ja) * 2000-02-25 2002-07-16 Japan Tobacco Inc ベンズアミド誘導体及びその用途
JP5306194B2 (ja) * 2006-06-22 2013-10-02 アナディス ファーマシューティカルズ インク ピロ［１，２−ｂ］ピリダジノン化合物
JP2011231094A (ja) * 2009-11-02 2011-11-17 Neurotherapeutics Pharma Inc ブメタニド、フロセミド、ピレタニド、アゾセミド、およびトルセミドのアナログ、組成物および使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1471237A (en) * 1974-03-18 1977-04-21 Hoechst Ag Basically substituted benzenesulphonamides and process for preparing them
EP0056970A1 (de) * 1981-01-22 1982-08-04 Hoechst Aktiengesellschaft Basisch substituierte Anthranilsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2000042004A1 (fr) * 1999-01-15 2000-07-20 Universite De Liege Derives de sulfonamides benzeniques et leurs utilisations
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
WO2007058960A1 (en) * 2005-11-10 2007-05-24 Adolor Corporation Sulfamoyl benzamides as cannabinoid receptor modulators
WO2008052190A2 (en) * 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2010085352A2 (en) * 2009-01-22 2010-07-29 Neurotherapeutics Pharma, Inc. Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
D'AMBROSIO KATIA ET AL:, CARBONIC ANHYDRASE INHIBITORS: BIOREDUCTIVE NITRO-CONTAINING SULFONAMIDES WITH SELECTIVITY FOR TARGETING THE TUMOR ASSOCIATED ISOFORMS IX AND XII, 1 June 2008 (2008-06-01) *
DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 APRIL 2018 (2018-04-19),, 3-(AMINOSULFONYL)-4-(BUTYLAMINO)-BENZOIC ACID, 19 April 2018 (2018-04-19) *
DATABASE REGISTRY [ONLINE]CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 APRIL 2018 (2018-04-19),, 4-(BUTYLAMINO)-3-[(METHYLAMINO)SULFONYL]BENZOIC ACID, 19 April 2018 (2018-04-19) *
JENNIFER D. PENSCHOW ET AL,, EFFECTS OF DIURETICS ON RENAL KALLIKREIN GENE EXPRESSION IN RATS, 1 November 1998 (1998-11-01) *
PETER W. FEIT ET AL,, AMINOBENZOIC ACID DIURETICS. 3. 4-SUBSTITUTED 5-SULFAMYLANTHRANILIC ACID DERIVATIVES, 1 January 1972 (1972-01-01) *
PIERRE FRANCOTTE ET AL,, NEW FLUORINATED 1,2,4-BENZOTHIADIAZINE 1,1-DIOXIDES: DISCOVERY OF AN ORALLY ACTIVE COGNITIVE ENHANCER ACTING THROUGH POTENTIATION OF THE 2-AMINO-3-(3-HYDROXY-5-METHYLISOXAZOL-4-YL)PROPIONIC ACID RECEPTORS, 25 February 2010 (2010-02-25) *

Also Published As

Publication number Publication date
US20220184008A1 (en) 2022-06-16
CA3135339A1 (en) 2020-10-08
IL286900A (en) 2021-10-31
CN120661491A (zh) 2025-09-19
CN114174259A (zh) 2022-03-11
AU2020251023A1 (en) 2021-11-04
EP3947345A1 (en) 2022-02-09
JP7676317B2 (ja) 2025-05-14
IL286900B1 (en) 2024-11-01
WO2020202072A1 (en) 2020-10-08
SG11202110950XA (en) 2021-10-28
KR20220022051A (ko) 2022-02-23
BR112021019935A2 (pt) 2022-03-03
AU2020251023B2 (en) 2025-11-27
JP2022528271A (ja) 2022-06-09

Similar Documents

Publication Publication Date Title
EP2968330B1 (en) Compounds and methods for inducing chondrogenesis
ES2911707T3 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y atoinmunitarias
CA3004297A1 (en) 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US10227349B2 (en) Pyrazolo[1,5-a]pyrimidine compound
EA026362B1 (ru) Производные бицикло[3.2.1]октиламида и их применение
CN116947880A (zh) 芳基受体调制剂及其制备和使用方法
BR112020020464A2 (pt) Derivados de bumetanida para a terapia da hiperidrose
IL286900B2 (en) Intracellular chloride concentration modulators
CN107531642B (zh) 咪唑衍生物
CA3146439A1 (en) 1-(6-(methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway diseases
WO2010010935A1 (ja) 光学活性なヘテロシクリデン－ｎ－アリールアセトアミド誘導体
JP2020514341A (ja) 薬理学的に活性なアリール置換ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2019193161A1 (en) Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
CN117580831A (zh) Grk2抑制剂及其用途
JP6831376B2 (ja) トリアゾール誘導体
RU2852940C2 (ru) Модуляторы внутриклеточной концентрации хлоридов
BR112021019935B1 (pt) Composto, uso do composto e composição farmacêutica
CN116283927A (zh) 嘧啶氨基芳基丙氨酸类衍生物及其作为富亮氨酸重复激酶2抑制剂的应用
TW202123931A (zh) 治療發炎性腸道疾病的化合物與方法
WO2010010933A1 (ja) ヘテロシクリデン－ｎ－（３，４－ジヒドロ－２（１ｈ）－キナゾリノン－５－イル）アセトアミド誘導体
WO2019088057A1 (ja) アニリド誘導体及びその医薬用途
JPS62283964A (ja) ベンズイミダゾール誘導体薬剤組成物
WO2019044940A1 (ja) 環状アミン誘導体及びその医薬用途